Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients

Diseases of the Colon and Rectum

Volumn 54, Issue 9, 2011, Pages 1098-1106

  Shinto, Eiji ^a   Hashiguchi, Yojiro ^a   Ueno, Hideki ^a   Kobayashi, Hirotoshi ^b   Ishiguro, Megumi ^b   Mochizuki, Hidetaka ^a   Yamamoto, Junji ^a   Hase, Kazuo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

CD133; Chemoradiotherapy; Cyclooxygenase 2; Rectal cancer; Tumor regression grading

Indexed keywords

CD133 ANTIGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21; PROTEIN P27; PROTEIN P53; UFT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURGERY; CHEMORADIOTHERAPY; COLONOSCOPY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FIBROSIS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RECTUM BIOPSY; RECTUM CARCINOMA; RECTUM RESECTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; CHI-SQUARE DISTRIBUTION; COLONOSCOPY; CYCLOOXYGENASE 2; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URACIL;

EID: 80052699953     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e3182218155     Document Type: Article

References (40)

1. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999; 44: 1027-1038. (Pubitemid 29342903)
2. Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002; 45: 895-903. (Pubitemid 34761469)
3. Kaminsky-Forrett MC, Conroy T, Luporsi E, et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys. 1998; 42: 935-941. (Pubitemid 29004132)
4. Chan AK, Wong AO, Langevin J, et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys. 2000; 48: 843-856.
5. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: longterm follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005; 23: 8697-8705. (Pubitemid 46211513)
6. Stelzmueller I, Zitt M, Aigner F, et al. Postoperative morbidity following chemoradiation for locally advanced low rectal cancer. J Gastrointest Surg. 2009; 13: 657-667.
7. Gervaz P, Rotholtz N, Pisano M, et al. Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer. Arch Surg. 2001; 136: 192-196. (Pubitemid 32143843)
8. Lin LC, Lee HH, Hwang WS, et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol. 2006; 15: 211-216.
9. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 673-688.
10. Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol. 1998; 5: 203-208. (Pubitemid 28249307)
11. Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, Mochizuki H. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy. Dis Colon Rectum. 2007; 50: 1354-1362. (Pubitemid 47472379)
12. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003; 4: 605-615. (Pubitemid 37258402)
13. Davis TW, O'Neal JM, Pagel MD, et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004; 64: 279-285. (Pubitemid 38114108)
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-115. (Pubitemid 46067311)
15. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106-110. (Pubitemid 46067310)
16. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010; 23: 450-457.
17. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007; 67: 8980-8984. (Pubitemid 47535877)
18. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative raradiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl J Med. 2001; 345: 638-646.
19. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12: 19-23. (Pubitemid 27138353)
20. Japanese Society for Cancer of Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 2nd English ed. Tokyo: Kanehara & Co. Ltd.; 2009.
21. Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008; 98: 1389-1397. (Pubitemid 351543575)
22. Prall F, Ostwald C, Nizze H, Barten M. Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol. 2004; 12: 111-121. (Pubitemid 38788759)
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345. (Pubitemid 38944402)
24. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004; 10: 8465-8471. (Pubitemid 40053411)
25. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971; 76: 378-382.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159-174. (Pubitemid 8054849)
27. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23: 8688-8696. (Pubitemid 46211512)
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-3988. (Pubitemid 36418143)
29. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396-401. (Pubitemid 39551674)
30. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol. 2008; 26: 2821-2827.
31. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007; 43: 935-946. (Pubitemid 46366698)
32. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132: 2542-2556. (Pubitemid 46890873)
33. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-760. (Pubitemid 44949604)
34. Chiou SH, Kao CL, Chen YW, et al. Identification of CD133 positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One. 2008; 3: e2090.
35. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys. 2007; 67: 1-5. (Pubitemid 44959518)
36. García-Aguilar J, Hernandez de Anda E, Sirivongs P, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003; 46: 298-304. (Pubitemid 36331646)
37. Kuo LJ, Liu MC, Jian JJ, et al. Is finalTNMstaging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol. 2007; 14: 2766-2772. (Pubitemid 47460637)
38. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I. Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis. 2005; 20: 440-445. (Pubitemid 41086420)
39. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008; 99: 1578-1583.
40. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99: 1285-1289.